[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2015KN00290A - - Google Patents

Info

Publication number
IN2015KN00290A
IN2015KN00290A IN290KON2015A IN2015KN00290A IN 2015KN00290 A IN2015KN00290 A IN 2015KN00290A IN 290KON2015 A IN290KON2015 A IN 290KON2015A IN 2015KN00290 A IN2015KN00290 A IN 2015KN00290A
Authority
IN
India
Prior art keywords
influenzae
nthi
antibody
medicine
treating
Prior art date
Application number
Other languages
English (en)
Inventor
Vega Masignani
Maria Arico
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of IN2015KN00290A publication Critical patent/IN2015KN00290A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN290KON2015 2004-05-14 2005-05-16 IN2015KN00290A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0410866.8A GB0410866D0 (en) 2004-05-14 2004-05-14 Haemophilius influenzae
PCT/IB2005/001775 WO2005111066A2 (fr) 2004-05-14 2005-05-16 Polypeptides issus d'haemophilus influenzae non typable

Publications (1)

Publication Number Publication Date
IN2015KN00290A true IN2015KN00290A (fr) 2015-06-12

Family

ID=32527109

Family Applications (1)

Application Number Title Priority Date Filing Date
IN290KON2015 IN2015KN00290A (fr) 2004-05-14 2005-05-16

Country Status (10)

Country Link
US (4) US7749518B2 (fr)
EP (5) EP2341069A1 (fr)
JP (2) JP2008506364A (fr)
CN (1) CN1997663A (fr)
BR (1) BRPI0511118A (fr)
CA (1) CA2566632A1 (fr)
GB (1) GB0410866D0 (fr)
IN (1) IN2015KN00290A (fr)
RU (1) RU2432357C2 (fr)
WO (1) WO2005111066A2 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1947187E (pt) * 2000-02-28 2011-07-04 Novartis Vaccines & Diagnostic Expressões híbridas de proteínas de neisseria
NZ562998A (en) * 2002-10-11 2008-05-30 Novartis Vaccines & Diagnostic Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
CA2602665A1 (fr) * 2005-03-30 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Haemophilus influenzae de type b
EP1899366A2 (fr) 2005-06-16 2008-03-19 Children's Hospital, Inc. Genes d'isolat d'otite moyenne de souche non typable haemophilus influenzae
EP2548884B1 (fr) 2005-08-10 2017-08-02 Arne Forsgren AB Interaction de moraxella catarrhalis avec des cellules épithéliales, des protéines matricielles extracellulaires et le système compleméntaire
US8617565B2 (en) * 2006-01-17 2013-12-31 Arne Forsgren et al. Surface exposed Haemophilus influenzae protein (protein E; pE)
US9132183B2 (en) * 2007-03-09 2015-09-15 Newport Laboratories Modified live (JMSO strain) Haemophilus parasuis vaccine
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
NZ593674A (en) * 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP2405938A2 (fr) * 2009-02-13 2012-01-18 Intercell AG Antigenes haemphilus influenzae non typables
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
EP2590626B1 (fr) 2010-07-06 2015-10-28 GlaxoSmithKline Biologicals SA Liposomes à lipides ayant une valeur de pka avantageuse pour la délivrance d'arn
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
BR112013000392B8 (pt) 2010-07-06 2022-10-04 Novartis Ag Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso
PT2591114T (pt) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Imunização de mamíferos de grande porte com doses baixas de arn
TR201908635T4 (tr) 2010-08-31 2019-07-22 Glaxosmithkline Biologicals Sa Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler.
HRP20221023T1 (hr) 2010-08-31 2022-11-11 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za isporuku rna koja kodira imunogen
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
JP2014516028A (ja) * 2011-05-11 2014-07-07 リースベック ヘルスケア スウェーデン アクティエボラーグ ラミニン及びビトロネクチン結合特性を有するタンパク質ｆ−新規インフルエンザ菌付着因子
BR112014000236A2 (pt) 2011-07-06 2017-02-14 Novartis Ag lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
DK2750707T3 (en) 2011-08-31 2019-02-11 Glaxosmithkline Biologicals Sa PEGYLED LIPOSOMES FOR DELIVERING IMMUNOGEN-CODING RNA
WO2013160335A2 (fr) * 2012-04-26 2013-10-31 Novartis Ag Antigènes et combinaisons d'antigènes
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
WO2014136086A1 (fr) 2013-03-08 2014-09-12 Novartis Ag Lipides et compositions lipidiques pour l'administration de principes actifs
US11274144B2 (en) * 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
PT3083556T (pt) 2013-12-19 2020-03-05 Novartis Ag Lípidos e composições lipídicas para a entrega de agentes ativos
ES2908827T3 (es) 2013-12-19 2022-05-04 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
EP3169309B1 (fr) 2014-07-16 2023-05-10 Novartis AG Procédé d'encapsulation d'un acide nucléique dans une nanoparticule lipidique hôte
AU2015307324B2 (en) * 2014-08-27 2020-02-06 Switchfloat Holdings Limited An oil field tubular and an internal sleeve for use therewith, and a method of deactivating a float valve within the oil field tubular
JP6731912B2 (ja) 2014-09-05 2020-07-29 ノバルティス アーゲー 活性物質の送達用の脂質および脂質組成物
EP3061826A1 (fr) 2015-02-27 2016-08-31 Novartis AG Réplicons du flavivirus
EP3307307A4 (fr) * 2015-06-09 2019-05-01 The Board of Regents of the University of Oklahoma Compositions et traitements pour haemophilus influenzae
EP3322408B1 (fr) 2015-07-14 2022-06-08 The Research Institute at Nationwide Children's Hospital Nouvelle formulation pour l'élimination de pathogènes cariogènes et opportunistes dans la cavité buccale
EP3328429A4 (fr) * 2015-07-31 2019-03-20 The Research Institute at Nationwide Children's Hospital Peptides et anticorps pour l'élimination de biofilms
WO2017066719A2 (fr) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Agents spécifiques interférant avec hu
EP3450446A1 (fr) * 2016-04-27 2019-03-06 Biocells (Beijing) Biotech Co., Ltd. Méthode de traitement de lésions liées à la neurotoxicité excitatrice
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3049114A1 (fr) * 2017-01-04 2018-07-12 Lauren O. Bakaletz Fragments d'anticorps pour le traitement de troubles lies au biofilm
CA3049105A1 (fr) 2017-01-04 2018-07-12 Lauren O. Bakaletz Anticorps et vaccins dnabii presentant une activite amelioree
US20180221468A1 (en) * 2017-01-19 2018-08-09 Iowa State University Research Foundation, Inc. Haemophilus influenzae immunogen
WO2018170178A1 (fr) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition et procédés de rupture de biofilms bactériens sans inflammation associée
US20220143168A1 (en) * 2019-02-27 2022-05-12 Evaxion Biotech A/S Vaccines targeting H. influenzae
AU2021228218A1 (en) * 2020-02-28 2022-09-01 Trait Biosciences, Inc. Novel systems, methods, and compositions for the glycosylation of cannabinoid compounds
US12116614B2 (en) 2020-06-30 2024-10-15 Research Institute At Nationwide Children's Hospital Methods for determining antibiotic sensitivity
EP4387597A1 (fr) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Lyophilisation de nanoparticules lipidiques (lnp) encapsulant de l'arn et leurs formulations
WO2023021421A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Vaccins à base d'arn lyophilisés à faible dose et leurs procédés de préparation et d'utilisation
CN114574456B (zh) * 2022-03-18 2022-08-12 华南理工大学 一种亚硝酸盐还原酶突变体及其编码基因和应用
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
CN116236575A (zh) * 2023-03-07 2023-06-09 北京化工大学 一种光控偶联型纳米探针及其制备方法、光控偶联的纳米颗粒组合物与应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB234768A (en) * 1924-05-28 1925-08-27 Ritter Dental Mfg Company Inc Improvements in adjustable brackets for supporting head-rests or other articles
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
WO1991001146A1 (fr) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine et supports d'hormone pour vaccins conjugues
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6245337B1 (en) * 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2302554C (fr) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Emulsions huile-dans-l'eau contenant des saponines
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR100585408B1 (ko) 1998-02-12 2006-06-01 와이어쓰 홀딩스 코포레이션 인터루킨-12로 제형된 폐렴구균 및 수막구균 백신
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2000023105A2 (fr) 1998-10-16 2000-04-27 Smithkline Beecham Biologicals S.A. Produits d'addition et vaccins
BR0009163A (pt) 1999-03-19 2001-12-26 Smithkline Beecham Biolog Vacina
CA2365914A1 (fr) 1999-04-09 2000-10-19 Techlab, Inc. Support proteique recombinant de la toxine a du clostridium recombinant pour vaccins conjugues polysaccharides
CA2383413A1 (fr) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Vaccins
AR025749A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
DK2270171T5 (da) 2000-10-02 2013-11-18 Id Biomedical Corp Quebec Haemophilus influenzae-antigener og tilsvarende DNA-fragmenter
GB0026002D0 (en) * 2000-10-24 2000-12-13 Smithkline Beecham Biolog Novel compounds
EP1328543B1 (fr) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Acides nucleiques et proteines derives des groupes de streptocoques a et b
GB0109289D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Novel compounds
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003009869A1 (fr) 2001-07-26 2003-02-06 Chiron Srl. Vaccins comprenant des adjuvants aluminium et histidine
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
WO2003024480A2 (fr) 2001-09-14 2003-03-27 Cytos Biotechnology Ag Activation in vivo de cellules presentant un antigene en vue d'augmenter les reponses immunes induites par des particules de type virus
WO2003035836A2 (fr) 2001-10-24 2003-05-01 Hybridon Inc. Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5'
GB0200025D0 (en) * 2002-01-02 2002-02-13 Glaxosmithkline Biolog Sa Novel compounds
US20060068386A1 (en) * 2002-03-04 2006-03-30 Alexei Slesarev Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
EP2330117A1 (fr) * 2003-03-06 2011-06-08 Nationwide Children's Hospital, Inc. Gènes d'otite moyenne isolée d'haemophilus influenzae non typable
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP1899366A2 (fr) 2005-06-16 2008-03-19 Children's Hospital, Inc. Genes d'isolat d'otite moyenne de souche non typable haemophilus influenzae
US8617565B2 (en) 2006-01-17 2013-12-31 Arne Forsgren et al. Surface exposed Haemophilus influenzae protein (protein E; pE)
AT507928B1 (de) 2008-06-30 2015-09-15 Coil Holding Gmbh Drosselspule für elektrische energieversorgungsnetze mit reduzierten schallemissionen
US9018858B2 (en) 2008-09-24 2015-04-28 B/E Aerospace, Inc. Calibration method for LED lighting systems

Also Published As

Publication number Publication date
BRPI0511118A (pt) 2007-11-27
RU2432357C2 (ru) 2011-10-27
EP2341069A1 (fr) 2011-07-06
WO2005111066A2 (fr) 2005-11-24
US7749518B2 (en) 2010-07-06
US9102729B2 (en) 2015-08-11
EP1745067A2 (fr) 2007-01-24
CA2566632A1 (fr) 2005-11-24
US20100303822A1 (en) 2010-12-02
EP2351773A1 (fr) 2011-08-03
CN1997663A (zh) 2007-07-11
RU2006144093A (ru) 2008-06-20
US8124098B2 (en) 2012-02-28
EP2343313A1 (fr) 2011-07-13
JP2008506364A (ja) 2008-03-06
WO2005111066A3 (fr) 2006-05-26
US20120148615A1 (en) 2012-06-14
US20140234363A1 (en) 2014-08-21
WO2005111066A8 (fr) 2007-05-18
JP2012000112A (ja) 2012-01-05
US20080267966A1 (en) 2008-10-30
GB0410866D0 (en) 2004-06-16
EP2351774A1 (fr) 2011-08-03

Similar Documents

Publication Publication Date Title
IN2015KN00290A (fr)
NZ591415A (en) Haemophilus influenzae type B
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DK1645631T3 (da) Neisseria antigener og præparater
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
DK1185691T3 (da) Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
EP2645106A3 (fr) Procédés et produits pour évaluer une réponse immunitaire à un agent thérapeutique
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
WO2004111081A3 (fr) Peptides antigeniques de coronavirus de sars, et utilisations
WO2003016464A3 (fr) Sequences d'oligosaccharides specifiques pour le cancer et leur utilisation
WO2002098355A3 (fr) Methodes et compositions pour diagnostic et traitement de la resistance a l'insuline et des etats associes
WO2004094476A3 (fr) Compositions et methodes se rapportant a stop-1
EP1536006A4 (fr) Antigenes cancereux et leur utilisation
WO2004066933A3 (fr) Compositions et methodes permettant de traiter le cancer au moyen de igsf9 et de liv-1
EP1667634A4 (fr) Vaccin contre l'anthrax
DE602004013752D1 (de) Oberflächenprotein aus Neisserien
EP1191096A4 (fr) Nouvelle proteine et son adn
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
EP1587928A4 (fr) Molecule d'acide nucleique humaine saa3, proteine, et procedes d'utilisation
EP1566386A4 (fr) Gene associe a la calvitie et polypeptide code par ce gene, et utilisations correspondantes
WO2007108903A3 (fr) Vaccins contre campylobacter et procedes d'utilisation
SE0202608D0 (sv) New sequences
BRPI0408023A (pt) métodos para previnir gliconoilação de proteìnas
WO2004031233A3 (fr) Nouveaux polypeptides de type chimiokine